Category Archives: Clinical Cardiology

Sept. 27, 2019 18:30 UTC Study in The Lancet successfully demonstrated endpoints of identifying both vulnerable patients and vulnerable plaques that are at significantly higher risk for subsequent major adverse cardiovascular events BEDFORD, Mass.--(BUSINESS WIRE)-- Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced that the Lipid-Rich Plaque (LRP) Study was published online today in The Lancet. The landmark study demonstrated that near-infrared spectroscopy (NIRS) imaging of non-obstructive areas in patients undergoing cardiac catheterization and possible percutaneous coronary intervention (PCI) was safe and can aid in identifying patients and artery segments at higher risk for subsequent non-culprit major adverse cardiovascular events (NC-MACE). Continue reading →

SAN FRANCISCO, CA I spent my second day at TCT 2019 sampling the excellent selection of practical educational opportunities in the TCT Training Pavilion and speaking to some of the professional staff supporting industry-led training programs. The last few years have seen a proliferation in the popularity of teaching pavilions at interventional cardiology conferences in which small group skill training is taught by experienced interventionalists, usually with the use of sophisticated procedural simulators. I found myself wondering: what has led to their rise in popularity, why are they found primarily at major meetings, and do they fulfill an important need Continue reading →

SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc Continue reading →

SAN FRANCISCO, CAAmong patients with severe aortic stenosis at low surgical risk, TAVR is associated with improved disease-specific health status over SAVR at not only 1 month but also 6 and 12 months, according to a PARTNER 3 substudy. Despite the fact that patients werent overly symptomatic at baseline, these patients still saw a large improvement in quality of life, Suzanne J. Continue reading →

September 25, 2019 Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized patients with de novo three-vessel and left main coronary artery disease, according to new research. The late-breaking results from the SYNTAX Extended Survival study were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. Continue reading →

SAN FRANCISCO, CAIn patients with severe, symptomatic tricuspid regurgitation (TR), a comparison pitting a range of different transcatheter interventions against medical therapy suggests that the these approaches are associated with a lower risk of death and hospitalization for heart failure, as well as a lower risk of all-cause mortality. The new propensity-matched analysis, which was presented at TCT 2019 and published simultaneously in the Journal of the American College of Cardiology, suggests that the rate of survival free from heart failure at 1 year was 51.3% among patients treated with medical therapy and 68.4% among those treated with a transcatheter option (P = 0.0003). The analysis drew on registry numbers that included outcomes for several devices currently being used for tricuspid disease under compassionate use Continue reading →

SAN FRANCISCO, CASCOPE I is the first of two head-to-head trials underway for the investigational Acurate Neo transcatheter device (Boston Scientific), this one a comparison against Sapien 3 (Edwards Lifesciences). In the first surprise of the morning, this trial failed to meet its primary endpoint of noninferiority at 30 days and, indeed, in additional analyses, the Sapien 3 valve was shown to be superior, at least a for the composite endpoint of safety and efficacy used in this study. That included all-cause death, any stroke, life-threatening or disabling bleeding, major vascular complications, coronary artery obstruction requiring intervention, acute kidney injury stage 2 or higher, valve-related dysfunction requiring repeat procedure, rehospitalization for valve-related symptoms or congestive heart failure, moderate or severe prosthetic valve regurgitation or prosthetic valve stenosis at 30 days. Continue reading →

As Duval points out, the cardiologists needed training in the advanced functionalities such as echo strain analysis and the 3D analysis embedded in the application. They needed image viewing to be closely integrated with the Epic EMR Continue reading →

PHILADELPHIA Once again, the antidiabetic drug dapagliflozin (Farxiga, AstraZeneca) showed that the term "antidiabetic drug" doesn't really capture all that it might offer. In the randomized DEFINE-HF trial of patients with heart failure with reduced ejection fraction (HFrEF), either with or without type 2 diabetes, those who took dapagliflozin along with their standard heart failure meds rapidly showed fewer symptoms and improved quality of life Continue reading →

Novo Nordisk officials believe the new therapy will fufill an unmet need for patients with type 2 diabetes and obesity who need a GLP-1 receptor agonist but do not wish to use an injectable drug. The filings are based on thePIONEER clinical trial programfor oral semaglutide, which included a cardiovascular outcomes trial Continue reading →